Clinical Trials Directory

Trials / Completed

CompletedNCT01823887

Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Cyberonics, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The ANTHEM-HF Study is designed to demonstrate the safety and efficacy of vagus nerve stimulation (VNS) with the Cyberonics VNS Therapy System for the treatment of subjects with symptomatic heart failure.

Detailed description

Heart failure patients will be enrolled and randomized to cervical VNS implantation on either the left side or right side. After a 2-week post-implantation recovery period and a 10-week stimulation titration period, continuous periodic stimulation will be performed for 6 months, with data collection at 3 months and 6 months.

Conditions

Interventions

TypeNameDescription
DEVICEVagus Nerve Stimulation (VNS)Electrical Stimulation of the Vagus Nerve

Timeline

Start date
2012-07-01
Primary completion
2014-04-01
Completion
2014-06-01
First posted
2013-04-04
Last updated
2015-02-19

Locations

1 site across 1 country: India

Source: ClinicalTrials.gov record NCT01823887. Inclusion in this directory is not an endorsement.

Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study (NCT01823887) · Clinical Trials Directory